在鼻咽癌患者血清中,常可测到高滴度的抗Epstein-Barr(EB)病毒多种特异性抗原的抗体。其中,抗EB病毒壳抗原(VCA)的特异性免疫球蛋白A抗体VCA-IgA更具特异性,已被广泛应用于临床。鼻咽癌患者血清VCA-IgA抗体的阳性率达90.14％及95.07％。然而,这一血清学诊断不能单独作为确诊鼻咽癌的依据,只是一种辅助方法。为了确定其在帮助发现鼻咽癌病例上的意义,我们 In the serum of patients with nasopharyngeal carcinoma, high titer antibodies against multiple specific antigens of Epstein-Barr (EB) virus can be detected. Among them, the specific immunoglobulin A antibody VCA-IgA against the EB virus shell antigen (VCA) is more specific and has been widely used in clinical practice. The positive rate of serum VCA-IgA antibody in nasopharyngeal carcinoma patients was 90.14% and 95.07%. However, this serological diagnosis alone cannot be used as a basis for the diagnosis of nasopharyngeal carcinoma. It is only a supplementary method. In order to determine its significance in helping to find cases of nasopharyngeal carcinoma, we